Arvinas, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arvinas, Inc. (ARVN) on December 8, 2025, covering events reported on December 6, 2025. The filing discloses preclinical data for ARV-393, a PROTAC BCL6 degrader, presented at the 67th American Society of Hematology (ASH) Annual Meeting.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on scientific and clinical development updates.
Material Changes and Scientific Highlights
The Company announced significant preclinical findings regarding the combination of ARV-393 and glofitamab (a CD20×CD3 bispecific antibody) in a humanized high-grade B-cell lymphoma (HGBCL) xenograft model:
- Tumor Growth Inhibition (TGI): The combination achieved 81% TGI with concomitant dosing and 91% TGI with sequential dosing (ARV-393 followed by glofitamab), compared to 38% for single-agent ARV-393 and 36% for glofitamab alone.
- Tumor Regression: At a higher ARV-393 dose (6 mg/kg), tumor regression was observed in 10 of 10 mice (concomitant) and 7 of 8 mice (sequential), versus 5 of 11 mice for single-agent ARV-393 and 0 of 11 for glofitamab alone.
- Mechanism: RNA sequencing indicated ARV-393 upregulated CD20 expression and interferon signaling genes while downregulating proliferation-associated genes, suggesting mechanistic synergy with T-cell engagement.
Guidance, Outlook, and Risks
Clinical Plans: ARV-393 is currently in a Phase 1 trial for relapsed/refractory non-Hodgkin lymphoma. The Company plans to share clinical data from this trial at a medical congress in 2026. Additionally, a glofitamab combination cohort for diffuse large B-cell lymphoma is planned for addition to the Phase 1 trial in 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to risks associated with clinical trial initiation, data presentation timing, and the inherent uncertainties of drug development. The Company assumes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the specific dosing schedules (concomitant vs. sequential) that yielded the highest tumor regression rates in the preclinical model.
- Confirm the timeline for the addition of the glofitamab combination cohort in the ongoing Phase 1 trial.
- Monitor upcoming medical congresses in 2026 for the release of clinical data from the ARV-393 Phase 1 trial.
- Review the full text of the press release (Exhibit 99.1) for detailed biomarker analysis and safety data not summarized in the 8-K.